Primary Sclerosing Cholangitis clinical trials at UCSF
2 in progress, 1 open to eligible people
Showing trials for
Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis
open to eligible people ages 18-75
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
San Francisco, California and other locations
Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
Sorry, in progress, not accepting new patients
The primary objective of this study is to evaluate the safety and tolerability of Cilofexor in adults with primary sclerosing cholangitis (PSC).
San Francisco, California and other locations
Last updated: